↓ Skip to main content

PLOS

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment

Overview of attention for article published in PLoS Computational Biology, May 2013
Altmetric Badge

Mentioned by

blogs
1 blog
policy
1 policy source

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
26 Mendeley
Title
Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
Published in
PLoS Computational Biology, May 2013
DOI 10.1371/journal.pcbi.1003066
Pubmed ID
Authors

Gouri Shankar Pandey, Chen Yanover, Tom E. Howard, Zuben E. Sauna

Abstract

The development of neutralizing anti-drug-antibodies to the Factor VIII protein-therapeutic is currently the most significant impediment to the effective management of hemophilia A. Common non-synonymous single nucleotide polymorphisms (ns-SNPs) in the F8 gene occur as six haplotypes in the human population (denoted H1 to H6) of which H3 and H4 have been associated with an increased risk of developing anti-drug antibodies. There is evidence that CD4+ T-cell response is essential for the development of anti-drug antibodies and such a response requires the presentation of the peptides by the MHC-class-II (MHC-II) molecules of the patient. We measured the binding and half-life of peptide-MHC-II complexes using synthetic peptides from regions of the Factor VIII protein where ns-SNPs occur and showed that these wild type peptides form stable complexes with six common MHC-II alleles, representing 46.5% of the North American population. Next, we compared the affinities computed by NetMHCIIpan, a neural network-based algorithm for MHC-II peptide binding prediction, to the experimentally measured values and concluded that these are in good agreement (area under the ROC-curve of 0.778 to 0.972 for the six MHC-II variants). Using a computational binding predictor, we were able to expand our analysis to (a) include all wild type peptides spanning each polymorphic position; and (b) consider more MHC-II variants, thus allowing for a better estimation of the risk for clinical manifestation of anti-drug antibodies in the entire population (or a specific sub-population). Analysis of these computational data confirmed that peptides which have the wild type sequence at positions where the polymorphisms associated with haplotypes H3, H4 and H5 occur bind MHC-II proteins significantly more than a negative control. Taken together, the experimental and computational results suggest that wild type peptides from polymorphic regions of FVIII constitute potential T-cell epitopes and thus could explain the increased incidence of anti-drug antibodies in hemophilia A patients with haplotypes H3 and H4.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Kenya 1 4%
Peru 1 4%
Unknown 24 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 23%
Student > Ph. D. Student 5 19%
Professor 3 12%
Student > Bachelor 2 8%
Other 2 8%
Other 5 19%
Unknown 3 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 11 42%
Biochemistry, Genetics and Molecular Biology 3 12%
Immunology and Microbiology 3 12%
Medicine and Dentistry 2 8%
Nursing and Health Professions 1 4%
Other 3 12%
Unknown 3 12%